Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Assets (2019 - 2026)

Alx Oncology Holdings' Assets history spans 5 years, with the latest figure at $242.6 million for Q4 2023.

  • On a quarterly basis, Assets fell 20.86% to $242.6 million in Q4 2023 year-over-year; TTM through Dec 2023 was $242.6 million, a 20.86% decrease, with the full-year FY2023 number at $242.6 million, down 20.86% from a year prior.
  • Assets hit $242.6 million in Q4 2023 for Alx Oncology Holdings, up from $220.1 million in the prior quarter.
  • Over the last five years, Assets for ALXO hit a ceiling of $436.1 million in Q4 2020 and a floor of $10.7 million in Q4 2019.
  • Historically, Assets has averaged $297.9 million across 5 years, with a median of $312.1 million in 2022.
  • Biggest five-year swings in Assets: skyrocketed 3984.43% in 2020 and later tumbled 30.72% in 2023.
  • Tracing ALXO's Assets over 5 years: stood at $10.7 million in 2019, then skyrocketed by 3984.43% to $436.1 million in 2020, then fell by 12.81% to $380.2 million in 2021, then dropped by 19.38% to $306.5 million in 2022, then decreased by 20.86% to $242.6 million in 2023.
  • Business Quant data shows Assets for ALXO at $242.6 million in Q4 2023, $220.1 million in Q3 2023, and $245.9 million in Q2 2023.